Literature DB >> 8847896

Splenectomy for poor graft function after allogeneic bone marrow transplantation in patients with chronic myeloid leukemia.

C Richard1, I Romón, M Perez-Encinas, J Baro, M J Rabuñal, F Mazorra, M Garcia de Polavieja, M Briz, M Ortin, A Iriondo, G Hermida, E Conde, J L Bello, A Zubizarreta.   

Abstract

We report four patients with chronic myeloid leukemia (CML) that showed poor graft function after a non-T-depleted bone marrow transplantation (BMT) from an HLA-compatible sibling donor and who were successfully treated with splenectomy. Conditioning was done with cyclophosphamide (CY) and total body irradiation (TBI) without additional splenic irradiation. Three patients had enlarged spleens before BMT. The nucleated cell dose infused ranged from 2.3-3.2 x 10(8)/kg. Bone marrow (BM) examination prior to splenectomy showed BM aplasia (three cases) or hypocellularity (one case). At splenectomy no patient had evidence of cytomegalovirus (CMV) infection or severe acute GVHD; and three patients had moderately enlarged spleens. All patients were transfusion dependent. Complete hematological recovery was obtained in all patients. BM cellularity was normal 1 month after splenectomy. Complete chimerism of donor origin was documented. The four patients are alive (+16 to +58 months after BMT). Thus, in patients with CML, a poor graft function may be successfully corrected by splenectomy.

Entities:  

Mesh:

Year:  1996        PMID: 8847896

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  2 in total

1.  Splenectomy as a measure to treat prolonged post-transplant cytopenia associated with hypersplenism.

Authors:  D L Brauer; A P Rapoport; S Yanovich; G Akpek
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

2.  Effects of spleen status on early outcomes after hematopoietic cell transplantation.

Authors:  G Akpek; M C Pasquini; B Logan; M-A Agovi; H M Lazarus; D I Marks; M Bornhaeüser; O Ringdén; R T Maziarz; V Gupta; U Popat; D Maharaj; B J Bolwell; J D Rizzo; K K Ballen; K R Cooke; P L McCarthy; V T Ho
Journal:  Bone Marrow Transplant       Date:  2012-12-10       Impact factor: 5.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.